drugset / Trial / NCT00859352

AZD1981 Midazolam CYP4503A Induction Study

NCT00859352

Phase 1 Completed 28 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelBasic science

Summary

The primary objective of the study is to investigate if the exposure of midazolam is clinically significantly changed by 14 days of exposure to AZD1981 through possible enzyme induction of CYP3A.

Timeline

Start
2009-03
Primary completion
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1981 Small molecule 100 mg Oral
Subject AZD1981 Small molecule 500 mg Oral
Subject Midazolam Small molecule 7.5 mg Oral

Indications

No indication recorded.